Alan I. Green, M.D.
Professor of Psychiatry
Professor of Pharmacology & Toxicology
Chairman, Department of Psychiatry
Director, SYNERGY: Dartmouth Center for Clinical and Translational Science
Associate Dean for Clinical and Translational Science, Geisel School of Medicine at Dartmouth
Associate Vice President for Health Affairs, Dartmouth College
Pharmacology & Toxicology
Columbia College, A.B. 1965
The Johns Hopkins University School of Medicine, M.D. 1969
Neuroscience Center at Dartmouth
New Hampshire-Dartmouth Psychiatric Research Center
Pharmacology and Toxicology Graduate Program
Program in Experimental and Molecular Medicine
Psychopharmacology Research Group
Geisel School of Medicine at Dartmouth, Department of Psychiatry
SYNERGY (Dartmouth Center for Clinical and Translational Science)
Neuroscience Center at Dartmouth
PEMM at Dartmouth
Department of Pharmacology and Toxicology at Dartmouth:
Department of Psychiatry
Geisel School of Medicine at Dartmouth
DHMC 1 Medical Center Drive
Lebanon NH 03756
Schizophrenia and comorbid substance use disorder
Neuropharmacology of psychosis
Neuropharmacology of substance use disorder
Early intervention in schizophrenia
Medication development for addiction
Dr. Green's research program, which involves clinical and neurobiological studies of patients with schizophrenia, particularly those with co-occurring substance use disorders, medication development studies for patients with alcoholism, and studies of alcohol drinking animals, has been funded by a series of grants from NIH, NARSAD and industry. He and his colleagues have proposed a neurobiological model suggesting that co-occurring substance use disorder in patients with schizophrenia relates, at least in part, to deficiencies in dopamine-mediated brain reward circuits. Data from his group have suggested that the novel antipsychotic medication clozapine limits alcohol and other substance use in these patients; he has proposed that the unique effects of clozapine in these patients relates to the mechanism of action of the drug, including its effects in brain reward circuits. On-going studies are continuing to probe the optimal psychopharmacological strategies for patients with co-occurring disorders through clinical trials, neuroimaging studies, and a series of investigations in animals.
Rotations and Thesis Projects:
1) Medication development for alcohol drinking in rodents.
2) Neuroimaging and brain reward circuitry in schizophrenia.
R21 AA019534 Green (PI) 04/01/2011 – 03/31/2014
NIAAA (No Cost Extension)
Alcoholism and Schizophrenia: A Translational Approach to Treatment
The major goal of this clinical trial is to begin to assess whether risperidone in combination with desipramine will limit alcohol use in patients with schizophrenia and alcohol use disorder.
R01DA032533 (Green) 07/15/2012 – 05/31/2016
Clozapine for cannabis use disorder in schizophrenia
This study aims primarily to determine the comparative ability of clozapine and risperidone to decrease cannabis use in patients with schizophrenia and cannabis use disorder. Other subsidiary aims will determine the comparative effects of these medications on psychiatric symptoms, neuropsychological functioning, and quality of life. Lastly, the study will explore whether patients with the val/val genotype at the COMT val158met locus are more likely to respond to clozapine than are those with the met/met or the val/met genotype.
Investigator-initiated Study (Industry) Green (PI) 02/15/2013 – 07/31/2014
Iloperidone for alcohol use disorder in schizophrenia
This study aims to assess whether iloperidone will decrease alcohol drinking in the Syrian golden hamster, and to assess whether desipramine added to iloperidone will decrease alcohol drinking in the Syrian golden hamster.
Graduate and Medical Pharmacology
Neuroscience of Psychiatric Disorders
Alan I. Green, M.D. is the Raymond Sobel Professor of Psychiatry, Professor of Pharmacology and Toxicology and Chairman of the Department of Psychiatry at Geisel School of Medicine at Dartmouth.
He received his B.A. from Columbia College and his M.D. degree from the Johns Hopkins University School of Medicine. Following an internship in medicine at the Beth Israel Hospital in Boston, he was a research associate at the National Institute of Mental Health and was Director of Biomedical Research at the Special Action Office for Drug Abuse Prevention in the Executive Office of the President. He did his psychiatry residency and a clinical research fellowship at the Harvard-based Massachusetts Mental Health Center. He joined the Harvard faculty in 1984 and was Director of the Commonwealth Research Center at Harvard Medical School from 1987 until 2002. He joined the Geisel School of Medicine's Department of Psychiatry as Professor and Chairman in November 2002. He has been a highly productive and active investigator, has received peer-reviewed funding throughout his career, has mentored over 30 trainees, and is the author of more than 250 papers and abstracts.
Chau DT, Roth RM, Green AI. The neural circuitry of reward and its relevance to psychiatric disorders. Curr Psychiatry Rep. 2004; 6(5):391-9. (view details on MedLine)
Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS; HGDH Research Group. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004; 66(2-3):125-35. (view details on MedLine)
Green AI, Chau DT, Keung WM, Dawson R, Mesholam RI, Schildkraut JJ. Clozapine reduces alcohol drinking in Syrian golden hamsters. Psychiatry Research. 2004; 128:9-20. (view details on MedLine)
Roth R, Brunette MF, Green AI. Treatment of substance use disorders in schizophrenia: A unifying neurobiological mechanism? Curr Psychiatry Rep. 2005; 7(4):283-91. (view details on MedLine)
Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB, HGDH Study Group. Olanzapine and haloperidol in first-episode psychosis: Two year data. Schizophrenia Research. 2006; 86(1-3):234-243. (view details on MedLine)
Green AI, Drake RE, Brunette MF, Noordsy DL. Schizophrenia and Co-Occurring Substance Use Disorder. American Journal of Psychiatry. 2007; 164(3):402-408. (view details on MedLine)
Green AI, Noordsy DL, Brunette MF, O'Keefe C Substance abuse and schizophrenia: Pharmacotherapeutic intervention. Journal of Substance Abuse Treatment. 2008; 34(1):61-71. (view details on MedLine)
Whitfield-Gabrieli S, Thermenos HW, Milanovic S, Tsuang MT, Faraone SV, McCarley RW, Shenton ME, Green AI, Nieto-Castanon A, LaViolette P, Wojcik J, Gabrieli JD, Seidman LJ. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proceedings of the National Academy of Sciences of the U S A. 2009 Jan 27;106(4):1279-84. (view details on MedLine)
Chau DT, Gulick D, Xie H, Dawson R, Green AI. Clozapine chronically suppresses alcohol drinking in Syrian golden hamsters. Neuropharmacology, 2010: 58(2): 351-356. (view details on MedLine)
Chau DT, Ahmed J, Wang TT, Xie H, Dawson R, Green AI. Raclopride lessens the ability of clozapine to suppress alcohol drinking in Syrian golden hamsters. Neuropharmacology, 2011: 61(4): 646-652. (view details on MedLine)